Zhang 2020b.

Study characteristics
Methods	Trial design: case report Type of publication: open‐access article Setting: inpatient/ICU Recruitment period: NR Country: China Language: English  Number of centres: 1 Trial registration number: NR (case report)  Date of trial registration: NR
Participants	Age: 64 years Gender: female Ethnicity: NR Number of participants (recruited/allocated/evaluated): 1 Severity of disease: severe Comorbidities: hypertension, diabetes Inclusion criteria: NR Exclusion criteria: NR Additional diagnoses: NR Previous treatments (e.g. experimental drug therapies, oxygen therapy, ventilation): mechanical ventilation
Interventions	CP therapy or hyperimmune immunoglobulin therapy: CP  Details of CP: Type of plasma: IgM reactive plasma; free of hepatitis B and C virus, HIV, syphilis, and residual SARS‐CoV‐2 Volume: 200 mL Number of doses: unclear Type of antibody test and antibody‐titre: IgG titrated by semiquantitative ELISA: 1:1: 6.59; 1:10: 5.33; 1:20: 4.87; 1:40: 3.87; 1:80: 3.24; 1:160: 2.20; 1:320: 2.17/> 1:160 Pathogen inactivated or not: NR RT‐PCR tested: NR Details of donors:  Gender: 4 male, 2 female, HLA and HNA antibody‐negative: NR Severity of disease: laboratory‐confirmed SARS‐CoV‐2 infection Timing from recovery from disease: NR RT‐PCR tested: recovery certificated by 2 consecutively negative SARS‐CoV‐2 PCR assay Treatment details, including time of plasma therapy (e.g. early stage of disease): 1 week after admission to ICU For studies including a control group: comparator (type): not applicable Concomitant therapy: NR Duration of follow‐up:  11 days after transfusion; then transferred to general ward Treatment cross‐overs: none Compliance with assigned treatment: good (compliant), transferred to general ward
Outcomes	Primary study outcome: antibody levels in CP Primary review outcomes All‐cause mortality at hospital discharge: reported Time to death: not applicable Secondary review outcomes Number of participants with grade 3 and grade 4 AEs, including potential relationship between intervention and adverse reaction (e.g. TRALI, transfusion‐transmitted infection, TACO, TAD, acute transfusion reactions): none Number of participants with SAEs: none Improvement of clinical symptoms, assessed through need for respiratory support at up to 7 days; 8‐15 days; 16‐30 days: reported for day 11 30‐day and 90‐day mortality: NR (all alive) Admission on the ICU: reported  Length of stay on the ICU: reported  Time to discharge from hospital: remains on general ward Additional study outcomes: lymphocyte count, renal and liver function, prothrombin time, CPK, LDH and myocardial enzymes
Notes	Sponsor/funding: "this study was supported by Medical Science and Technology Development Foundation, Nanjing Department of Health (ZKX18050). Dr. Xiang Xue is supported by the National Institutes of Health (K01DK114390) and a Research Scholar Grant from the American Cancer Society (RSG‐18‐050‐01‐NEC)." COIs: declared to have no conflicts of interest Other: case series focusing on CP donors